Tel: +44 (0)1223 316 855
life science research products, biological research products, biotechnology
close ...

Product types:
Flexible Human & Rat Complement ELISAs

Upgrading Your Laser Scanner? Consider The Sapphire™

Comprehensive in vitro proarrhythmia assay (CIPA)

Cambridge Bioscience, through B’SYS, offers access to a fully defined, comprehensive in vitro proarrhythmia assay (CIPA) package addressing the CIPA Initiative which will replace existing ICH S7a/b guidelines.

Combining cardiac ion channel panel screening (using pharmacological profiling through classical patch clamp electrophysiology) and the screening of validated beating iPSC human cardiomyocytes (on the multiple-electrode array (MEA) against reference compounds with known clinical outcomes), this service provides a more comprehensive screening than measuring hERG-induced QT prolongation alone.


Benefits Of Using This CIPA Package
• High quality data
• Comprehensive cardiac safety screen
• Multiple ion channel effects screen included - testing for hERG, Cav1.2 & Nav1.5
• Low to high throughput formats available
• Superior to hERG model in predicting Torsade de Pointes
• Fast 2-4 week timeline

CIPA Package Using Stem Cell-Derived Human Cardiomyocytes (SC-hCMs)

CIPA voltage

Example of CIPA voltage protocol for hERG (IKr)

MEA analysis

Example of MEA analysis using the Nanion CardioExcyte96™, combining impedance (IMP, cell contractility) and electrical field potential (EFP) measurements to investigate short- and long-term pharmacological effects on cardiomyocytes, including beat rate, beating accuracy, amplitude, rise/fall time and pulse width of the IMP signal as well as the amplitude and field potential duration of the EFP signal. The assay provides information on drug-induced alteration or impairment of contractility and EFP of SC-hCMs.

Contact our specialists
To discuss a CIPA package project, please contact our B'SYS specialist.

Contact Our B'SYS Specialist, Vashu